Purpose or Objective: Since 2014, the VERO system equipped with dynamic tracking DT has been used in our center for lung SBRT.The purpose of this work is to compare 2 compensation techniques for lung SBRT, DT and a method based on the definition of an ITV, in terms of PTV volume reduction and treatment time.
Material and Methods:
The VERO is an O ring system equipped with a gimbaled linac allowing pan and tilt rotations and with a stereoscopic dual-source kV X-ray imaging allowing the guidance of the tracking. A 4DCT is done to measure the range of the target movements with the breath: if the amplitude is < 7mm, an ITV is determined on the MIP images and if it is > 7mm, the DT method is preferred. A gold marker (Visicoil, IBA) is then implanted in the lesion and a new 4DCT is realized 1 week later. The GTVDT is drawn on the exhale phase and the PTVDT is defined with a 5mm margin. The dose is prescribed on the isodose covering 95 % of the PTV (Monte Carlo): the peripheral tumors receive 3x17 Gy, near the thoracic wall 4x12 Gy and near the mediastin 8x7,5 Gy. The metastatic diseases received 5x10 Gy. For DT, treatments are delivered with 6-8 no coplanar beams.
Results: 77 patients were treated with lung SBRT, including 22 patients treated with DT. Among these 22 patients, the PTVITV was however estimated: the average size of the PTVDT was 28.8cc(6.5 -14.3 cc) and that of the PTVITV was 46.4cc(10.4 in 139 cc), so a 40 % reduction of the PTV volume. The average session length in DT was 35 min, the same as with the ITV method. The breathing rate of the patients was often irregular during the session and especially compared with the reference 4DCT. It did not affect the treatment delivery neither the guidance of the tracking. The clinical tolerance during and after the SBRT with tracking was excellent: 1 patient that was already treated for interstitial pulmonary fibrosis developed symptomatic radiation pneumonitis (RP). 5 other patients had radiological RP on the CT done during their first 6 months follow up period ; all of them received corticosteroid therapy and did not show any symptoms. There was no chest wall toxicity. Over a 16 months follow-up,1 patient did not benefit from treatment with DT SBRT and had a progressive disease.
Conclusion:
With a 40% reduction of the PTV, this DT technique makes it easy to monitor all the patients breathing motion, including very irregular rates, in a treatment time equivalent to more classical techniques based on the ITV. Purpose or Objective: Local failure in lung cancer is associated with extremely poor survival. This study tested whether the pattern of failure is associated with the most PET avid volume in the pre-therapeutic PET/CT scan.
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Material and Methods:
Patients with inoperable NSCLC treated in our department between 2008 and 2010 were reviewed. Forty patients, who received radiotherapy (RT) for NSCLC and had an accessible pre-therapeutic FDG PET/CT scanning, were included. Fifteen of the patients developed local failure as the first event. Patient and tumour characteristics for patients with recurrences are presented in Table 1 . The peak SUV area in the pre-therapeutic PET/CT scan in both tumor and lymph nodes were identified by an experienced nuclear physician who delineated the volume encompassing 50% of the maximum SUV (SUVmax50) in all fifteen patients. All patients were followed by CT scans every third month. The CT scans which showed recurrences (rCT) were imported to the Eclipse treatment planning system (Varian MS) and the recurrence gross tumor volume(s) (rGTV) was delineated. A rigid registration between pre-therapeutic PET/CT and treatment planning CT (pCT) was performed using a soft tissue match on the tumor or the lymph nodes in SmartAdapt (Varian MS). The SUVmax50 volumes were copied to pCT using the rigid registration. The rCT with the defined rGTV were also fused with the pCT using a rigid registration based on normal tissue nearby the rGTV but excluding the rGTV. The vertebral column or the aortic arch was found to be preferable. Two radiation oncologists assessed the rigid registration between pCT and rCT.
Results:
The patients received conventionally fractionated RT with a total dose of 60-66 Gy. Planning target volumes (PTV) ranged from 169 cm3 to 1065 cm3 (mean = 678 cm3). Median time to local progression was seven months (95% CI 5-9 months). In twelve patients, the recurrences of the primary tumor appeared inside the PTV. In three cases, the recurrences were both inside and outside the PTV. These three recurrences outside the PTV appeared in mediastinal lymph node region. The rGTV overlapped with the pretherapeutic PET sub-volumes in twelve patients (Figure 1) . In one case, rGTV was near the PET sub-volume area without overlapping. In one patient, part of the target was missed because an atelectasis obscured the PET/CT signal and made the delineation of GTV less optimal.
